Antengene Corporation Ltd
HKEX:6996
Antengene Corporation Ltd
Research & Development
Antengene Corporation Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Research & Development
-¥258.9m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Research & Development
-¥5.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-40%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Research & Development
-¥2.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Research & Development
-¥7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Research & Development
-¥356.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Research & Development
-¥1.4B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Research & Development?
Research & Development
-258.9m
CNY
Based on the financial report for Dec 31, 2024, Antengene Corporation Ltd's Research & Development amounts to -258.9m CNY.
What is Antengene Corporation Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-17%
Over the last year, the Research & Development growth was 36%. The average annual Research & Development growth rates for Antengene Corporation Ltd have been 14% over the past three years , -17% over the past five years .
